Challenges and opportunities in rare tumor research

Chugai, a Japan­ese phar­ma owned by Roche, is part­ner­ing with a small Swiss biotech to work on next-gen­er­a­tion an­ti­body-drug con­ju­gates that de­liv­er mul­ti­ple cy­to­tox­ic mol­e­cules

Ipsen and Gen­fit re­vealed on Mon­day that their pri­ma­ry bil­iary cholan­gi­tis (PBC) drug can­di­date has met ad­di­tion­al end­points in a reg­is­tra­tional tri­al, adding fu­el to